All 32 patients with bowel cancer who took part in a groundbreaking UK trial have seen no return of their disease three years ...

From infections and allergies to brain diseases and autoimmune disorders, a wave of trials offers hope ...

Ivonescimab reduced the risk of death by one-third compared to chemotherapy in a China-based study that’s seen as an ...

Akeso’s Phase 3 ASCO data show ivonescimab improved overall survival vs PD-1 chemo in squamous NSCLC—key read for investors.

An experimental drug developed by China-based Akeso helped patients with advanced squamous non-small cell lung cancer live 15% longer than BeOne Medicines' immunotherapy Tevimbra, and cut the risk ...

Chemotherapy often did not work, but newer immunotherapy treatments are now helping save lives. Jeff Hill has spent his ...

UK scientists find tocilizumab, commonly used for rheumatoid arthritis, may help antidepressant-resistant patients ...

From cell-manufacturing laboratories to outpatient infusion facilities, health systems are rapidly adapting to a new kind of cancer treatment that demands individualized care, infrastructure and ...

New research reveals PD-1 inhibitors may compromise the blood-brain barrier, influencing cancer treatment outcomes and brain metastasis risks.

Immunotherapies such as so-called checkpoint inhibitors activate the body's own immune system to fight cancer cells and have revolutionized the treatment of many types of tumor. In breast cancer, ...